Updates in the Diffuse Large B-Cell Lymphoma Treatment Landscape

During JADPRO Live Virtual 2021, presenters discussed updates in the treatment of diffuse large B-cell lymphoma (DLBCL), including novel agents and chimeric antigen receptor (CAR) T-cell therapy, and how the treatment and management of patients with DLBCL has been affected by the COVID-19 pandemic.

Detalles Bibliográficos
Autores principales: Ames, Ashley, Lee, Diane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2022
Materias:
Meeting Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126354/
https://www.ncbi.nlm.nih.gov/pubmed/35663173
http://dx.doi.org/10.6004/jadpro.2022.13.3.33
Descripción
Sumario:During JADPRO Live Virtual 2021, presenters discussed updates in the treatment of diffuse large B-cell lymphoma (DLBCL), including novel agents and chimeric antigen receptor (CAR) T-cell therapy, and how the treatment and management of patients with DLBCL has been affected by the COVID-19 pandemic.

Ejemplares similares